NovoCure Limited公布了其关键三期Trident试验的顶线结果。该研究旨在评估肿瘤电场疗法在初诊胶质母细胞瘤患者中更早介入的疗效与安全性。
胶质母细胞瘤是一种极具侵袭性的脑癌，治疗选择有限。肿瘤电场疗法是一种利用特定频率电场干扰癌细胞分裂的物理疗法。Trident试验探索了在标准治疗方案（包括手术、放疗和化疗）基础上，于更早阶段联合使用该疗法是否能带来更佳的临床获益。
此次公布的顶线数据为后续的详细分析和在学术会议及同行评审期刊上的完整结果发布奠定了基础。公司表示，这些数据将用于支持与全球监管机构的沟通，以探讨该疗法在更广泛患者群体中应用的潜在路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.